Suzhou Genhouse Bio MAT2A compound 39

Suzhou Genhouse Bio MAT2A compound 39: sourced facts only. name: "Further optimization led to compound 39, which has a high potency for inhibiting MAT2A and a remarkable selectivity for MTAP-deleted cancer cell lines." [PMID:38818879]; target: "Further optimization led to compound 39, which has a high potency for inhibiting MAT2A and a remarkable selectivity for MTAP-deleted cancer cell lines." [PMID:38818879]; developer: "Center for Drug Design and Development, Suzhou Genhouse Bio Co., Ltd., No. 1 Xinze Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, China." [PMID:38818879]; stage: "Compound 39 has a favorable pharmacokinetic profile with high plasma exposure and oral bioavailability, and it exhibits significant efficacy in xenograft MTAP-depleted models." [PMID:38818879]